Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN)
Read more at globenewswire.comClimb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
Provided By GlobeNewswire – Last update: